## Ruben Abagyan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2064286/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders. European Journal of Medicinal Chemistry, 2022, 229, 114054.	2.6	11
2	Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events. PLoS ONE, 2022, 17, e0263402.	1.1	7
3	Mapping the gene network landscape of Alzheimer's disease through integrating genomics and transcriptomics. PLoS Computational Biology, 2022, 18, e1009903.	1.5	9
4	Control of Unsaturation in <i>De Novo</i> Fatty Acid Biosynthesis by FabA. Biochemistry, 2022, 61, 608-615.	1.2	2
5	Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L. Pharmaceuticals, 2022, 15, 744.	1.7	5
6	Biomimetic microbioreactor-supramolecular nanovesicles improve enzyme therapy of hepatic cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2021, 31, 102311.	1.7	2
7	Protein–protein interaction based substrate control in the <i>E. coli</i> octanoic acid transferase, LipB. RSC Chemical Biology, 2021, 2, 1466-1473.	2.0	6
8	Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds. PLoS Neglected Tropical Diseases, 2021, 15, e0008425.	1.3	10
9	Mtor inhibitors associated with higher cardiovascular adverse events—A large population database analysis. Clinical Transplantation, 2021, 35, e14228.	0.8	5
10	Elucidation of transient protein-protein interactions within carrier protein-dependent biosynthesis. Communications Biology, 2021, 4, 340.	2.0	23
11	Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Scientific Reports, 2021, 11, 5997.	1.6	19
12	Structure based design and synthesis of novel Toll-like Receptor 2 (TLR 2) lipid antagonists. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127861.	1.0	7
13	Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Scientific Reports, 2021, 11, 17324.	1.6	24
14	Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge. PLoS Computational Biology, 2021, 17, e1009302.	1.5	7
15	Molecular Properties of Drugs Handled by Kidney OATs and Liver OATPs Revealed by Chemoinformatics and Machine Learning: Implications for Kidney and Liver Disease. Pharmaceutics, 2021, 13, 1720.	2.0	12
16	Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database. Frontiers in Psychiatry, 2021, 12, 824288.	1.3	6
17	Common osteoporosis drug associated with increased rates of depression and anxiety. Scientific Reports, 2021, 11, 23956.	1.6	18
18	Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety. Scientific Reports, 2021, 11, 24173.	1.6	13

#	Article	IF	CITATIONS
19	Recommendations for Improving Methods and Models for Aquatic Hazard Assessment of Ionizable Organic Chemicals. Environmental Toxicology and Chemistry, 2020, 39, 269-286.	2.2	42
20	Unique metabolite preferences of the drug transporters OAT1 and OAT3 analyzed by machine learning. Journal of Biological Chemistry, 2020, 295, 1829-1842.	1.6	39
21	Transcriptome and binding data indicate that citral inhibits single strand DNAâ€binding proteins. Physiologia Plantarum, 2020, 169, 99-109.	2.6	10
22	Differential activities of maize plant elicitor peptides as mediators of immune signaling and herbivore resistance. Plant Journal, 2020, 104, 1582-1602.	2.8	21
23	A receptor-like protein mediates plant immune responses to herbivore-associated molecular patterns. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 31510-31518.	3.3	86
24	Postmarketing safety surveillance data reveals antidepressant effects of botulinum toxin across various indications and injection sites. Scientific Reports, 2020, 10, 12851.	1.6	18
25	HMG-CoA Reductase Inhibitors as Drug Leads against <i>Naegleria fowleri</i> . ACS Chemical Neuroscience, 2020, 11, 3089-3096.	1.7	13
26	Synthesis, Optimization, Antifungal Activity, Selectivity, and CYP51 Binding of New 2-Aryl-3-azolyl-1-indolyl-propan-2-ols. Pharmaceuticals, 2020, 13, 186.	1.7	12
27	Cardiac adverse events associated with chloroquine and hydroxychloroquine exposure in 20Âyears of drug safety surveillance reports. Scientific Reports, 2020, 10, 19199.	1.6	14
28	Cytomembrane-mimicking nanocarriers with a scaffold consisting of a CD44-targeted endogenous component for effective asparaginase supramolecule delivery. Nanoscale, 2020, 12, 12083-12097.	2.8	13
29	Biomimetic Membrane-Structured Nanovesicles Carrying a Supramolecular Enzyme to Cure Lung Cancer. ACS Applied Materials & Interfaces, 2020, 12, 31112-31123.	4.0	16
30	Systems Biology Analysis Reveals Eight SLC22 Transporter Subgroups, Including OATs, OCTs, and OCTNs. International Journal of Molecular Sciences, 2020, 21, 1791.	1.8	44
31	Biomimetic polysaccharide-cloaked lipidic nanovesicles/microassemblies for improving the enzymatic activity and prolonging the action time for hyperuricemia treatment. Nanoscale, 2020, 12, 15222-15235.	2.8	14
32	Druggable exosites of the human kino-pocketome. Journal of Computer-Aided Molecular Design, 2020, 34, 219-230.	1.3	2
33	Crosslinking-guided geometry of a complete CXC receptor-chemokine complex and the basis of chemokine subfamily selectivity. PLoS Biology, 2020, 18, e3000656.	2.6	24
34	How can proton pump inhibitors damage central and peripheral nervous systems?. Neural Regeneration Research, 2020, 15, 2041.	1.6	6
35	Title is missing!. , 2020, 18, e3000656.		0
36	Title is missing!. , 2020, 18, e3000656.		0

#	Article	IF	CITATIONS
37	Title is missing!. , 2020, 18, e3000656.		Ο
38	Title is missing!. , 2020, 18, e3000656.		0
39	Title is missing!. , 2020, 18, e3000656.		0
40	Title is missing!. , 2020, 18, e3000656.		0
41	Hybrid receptor structure/ligand-based docking and activity prediction in ICM: development and evaluation in D3R Grand Challenge 3. Journal of Computer-Aided Molecular Design, 2019, 33, 35-46.	1.3	16
42	Macrocycle modeling in ICM: benchmarking and evaluation in D3R Grand Challenge 4. Journal of Computer-Aided Molecular Design, 2019, 33, 1057-1069.	1.3	8
43	Discovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors. Scientific Reports, 2019, 9, 15893.	1.6	18
44	Discovery of New Inhibitors of Hepatitis C Virus NS3/4A Protease and Its D168A Mutant. ACS Omega, 2019, 4, 16999-17008.	1.6	19
45	Retrospective analysis reveals significant association of hypoglycemia with tramadol and methadone in contrast to other opioids. Scientific Reports, 2019, 9, 12490.	1.6	34
46	Nilotinib, an approved leukemia drug, inhibits smoothened signaling in Hedgehog-dependent medulloblastoma. PLoS ONE, 2019, 14, e0214901.	1.1	4
47	Identification of Four Amoebicidal Nontoxic Compounds by a Molecular Docking Screen of <i>Naegleria fowleri</i> Sterol Δ8â~Δ7-Isomerase and Phenotypic Assays. ACS Infectious Diseases, 2019, 5, 2029-2038.	1.8	6
48	2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 2. Structure-Based Optimization and Investigation of Effects Specific to the Allosteric Mode of Action. Journal of Medicinal Chemistry, 2019, 62, 1817-1836.	2.9	17
49	2-Aminothiazole Derivatives as Selective Allosteric Modulators of the Protein Kinase CK2. 1. Identification of an Allosteric Binding Site. Journal of Medicinal Chemistry, 2019, 62, 1803-1816.	2.9	25
50	Population Scale Retrospective Analysis Reveals Potential Risk of Cholestasis in Pregnant Women Taking Omeprazole, Lansoprazole, and Amoxicillin. Interdisciplinary Sciences, Computational Life Sciences, 2019, 11, 273-281.	2.2	6
51	Extended Multitarget Pharmacology of Anticancer Drugs. Journal of Chemical Information and Modeling, 2019, 59, 3006-3017.	2.5	17
52	Analysis of postmarketing safety data for proton-pump inhibitors reveals increased propensity for renal injury, electrolyte abnormalities, and nephrolithiasis. Scientific Reports, 2019, 9, 2282.	1.6	48
53	Proton-pump inhibitor use is associated with a broad spectrum of neurological adverse events including impaired hearing, vision, and memory. Scientific Reports, 2019, 9, 17280.	1.6	42
54	Multi-center screening of the Pathogen Box collection for schistosomiasis drug discovery. Parasites and Vectors, 2019, 12, 493.	1.0	20

#	Article	IF	CITATIONS
55	Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations. Journal of Biomolecular Structure and Dynamics, 2019, 37, 1043-1053.	2.0	20
56	Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia. American Journal of Psychiatry, 2018, 175, 674-682.	4.0	20
57	Hedgehog pathway and smoothened inhibitors in cancer therapies. Anti-Cancer Drugs, 2018, 29, 387-401.	0.7	31
58	Ligand-biased ensemble receptor docking (LigBEnD): a hybrid ligand/receptor structure-based approach. Journal of Computer-Aided Molecular Design, 2018, 32, 187-198.	1.3	39
59	Dexamethasone and Fludrocortisone Inhibit Hedgehog Signaling in Embryonic Cells. ACS Omega, 2018, 3, 12019-12025.	1.6	5
60	Population scale retrospective analysis reveals distinctive antidepressant and anxiolytic effects of diclofenac, ketoprofen and naproxen in patients with pain. PLoS ONE, 2018, 13, e0195521.	1.1	20
61	In silico discovery of small molecules that inhibit RfaH recruitment to RNA polymerase. Molecular Microbiology, 2018, 110, 128-142.	1.2	11
62	Protein-RNA Docking Using ICM. Journal of Chemical Theory and Computation, 2018, 14, 4971-4984.	2.3	15
63	Structural basis of ligand interaction with atypical chemokine receptor 3. Nature Communications, 2017, 8, 14135.	5.8	83
64	From Homology Models to a Set of Predictive Binding Pockets–a 5-HT <sub>1A</sub> Receptor Case Study. Journal of Chemical Information and Modeling, 2017, 57, 311-321.	2.5	23
65	Inhibition of PDE5A1 guanosine cyclic monophosphate (cGMP) hydrolysing activity by sildenafil analogues that inhibit cellular cGMP efflux. Journal of Pharmacy and Pharmacology, 2017, 69, 675-683.	1.2	6
66	Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications. Scientific Reports, 2017, 7, 1450.	1.6	23
67	Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV. Immunity, 2017, 46, 1005-1017.e5.	6.6	148
68	The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand. Nature Communications, 2017, 8, 1910.	5.8	66
69	Multi-targeting Drug Community Challenge. Cell Chemical Biology, 2017, 24, 1434-1435.	2.5	13
70	A Thiazole Orange Derivative Targeting the Bacterial Protein FtsZ Shows Potent Antibacterial Activity. Frontiers in Microbiology, 2017, 8, 855.	1.5	36
71	Flipping states: a few key residues decide the winning conformation of the only universally conserved transcription factor. Nucleic Acids Research, 2017, 45, 8835-8843.	6.5	28
72	Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target. PLoS Neglected Tropical Diseases, 2017, 11, e0005680.	1.3	36

#	Article	IF	CITATIONS
73	CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM). PLoS Neglected Tropical Diseases, 2017, 11, e0006104.	1.3	45
74	Analysis of drug binding pockets and repurposing opportunities for twelve essential enzymes of ESKAPE pathogens. PeerJ, 2017, 5, e3765.	0.9	5
75	Identifying ligands at orphan GPCRs: current status using structureâ€based approaches. British Journal of Pharmacology, 2016, 173, 2934-2951.	2.7	70
76	Environmental Photochemistry of Altrenogest: Photoisomerization to a Bioactive Product with Increased Environmental Persistence via Reversible Photohydration. Environmental Science & Technology, 2016, 50, 7480-7488.	4.6	21
77	Structure of CC chemokine receptor 2 with orthosteric and allosteric antagonists. Nature, 2016, 540, 458-461.	13.7	220
78	Molecular Properties of Drugs Interacting with SLC22 Transporters OAT1, OAT3, OCT1, and OCT2: A Machine-Learning Approach. Journal of Pharmacology and Experimental Therapeutics, 2016, 359, 215-229.	1.3	60
79	An Organic Anion Transporter 1 (OAT1)-centered Metabolic Network. Journal of Biological Chemistry, 2016, 291, 19474-19486.	1.6	39
80	SIRT2- and NRF2-Targeting Thiazole-Containing Compound with Therapeutic Activity in Huntington's Disease Models. Cell Chemical Biology, 2016, 23, 849-861.	2.5	71
81	An electrostatic mechanism for Ca2+-mediated regulation of gap junction channels. Nature Communications, 2016, 7, 8770.	5.8	119
82	Conformational Heterogeneity of Unbound Proteins Enhances Recognition in Protein–Protein Encounters. Journal of Chemical Theory and Computation, 2016, 12, 3236-3249.	2.3	11
83	Use of Cysteine Trapping to Map Spatial Approximations between Residues Contributing to the Helix N-capping Motif of Secretin and Distinct Residues within Each of the Extracellular Loops of Its Receptor. Journal of Biological Chemistry, 2016, 291, 5172-5184.	1.6	9
84	Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. Cell Research, 2016, 26, 574-592.	5.7	85
85	X-ray structures of thioredoxin and thioredoxin reductase from Entamoeba histolytica and prevailing hypothesis of the mechanism of Auranofin action. Journal of Structural Biology, 2016, 194, 180-190.	1.3	60
86	Membrane and Protein Interactions of the Pleckstrin Homology Domain Superfamily. Membranes, 2015, 5, 646-663.	1.4	42
87	Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada. PLoS ONE, 2015, 10, e0144337.	1.1	119
88	Development of a Highly Selective Allosteric Antagonist Radioligand for the Type 1 Cholecystokinin Receptor and Elucidation of Its Molecular Basis of Binding. Molecular Pharmacology, 2015, 87, 130-140.	1.0	10
89	How Does the Methodology of 3D Structure Preparation Influence the Quality of p <i>K</i> <sub>a</sub> Prediction?. Journal of Chemical Information and Modeling, 2015, 55, 1088-1097.	2.5	10
90	Molecular Mechanism of Action of Triazolobenzodiazepinone Agonists of the Type 1 Cholecystokinin Receptor. Possible Cooperativity across the Receptor Homodimeric Complex. Journal of Medicinal Chemistry, 2015, 58, 9562-9577.	2.9	15

Ruben Abagyan

#	Article	IF	CITATIONS
91	High-quality and universal empirical atomic charges for chemoinformatics applications. Journal of Cheminformatics, 2015, 7, 59.	2.8	32
92	Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. Science, 2015, 347, 1117-1122.	6.0	325
93	Histidine7.36(305) in the conserved peptide receptor activation domain of the gonadotropin releasing hormone receptor couples peptide binding and receptor activation. Molecular and Cellular Endocrinology, 2015, 402, 95-106.	1.6	4
94	Lanosterol reverses protein aggregation in cataracts. Nature, 2015, 523, 607-611.	13.7	351
95	Structure-Based Predictions of Activity Cliffs. Journal of Chemical Information and Modeling, 2015, 55, 1062-1076.	2.5	34
96	All-Atom Internal Coordinate Mechanics (ICM) Force Field for Hexopyranoses and Glycoproteins. Journal of Chemical Theory and Computation, 2015, 11, 2167-2186.	2.3	6
97	Activation of Gαi at the Golgi by GIV/Girdin Imposes Finiteness in Arf1 Signaling. Developmental Cell, 2015, 33, 189-203.	3.1	46
98	Shared Ligands Between Organic Anion Transporters (OAT1 and OAT6) and Odorant Receptors. Drug Metabolism and Disposition, 2015, 43, 1855-1863.	1.7	18
99	Experiment-Guided Molecular Modeling of Protein–Protein Complexes Involving GPCRs. Methods in Molecular Biology, 2015, 1335, 295-311.	0.4	11
100	A General Method for Site Specific Fluorescent Labeling of Recombinant Chemokines. PLoS ONE, 2014, 9, e81454.	1.1	21
101	Structureâ€based Design, Synthesis, and Biological Evaluation of Isatin Derivatives as Potential Glycosyltransferase Inhibitors. Chemical Biology and Drug Design, 2014, 84, 685-696.	1.5	19
102	Discovery of novel membrane binding structures and functions. Biochemistry and Cell Biology, 2014, 92, 555-563.	0.9	46
103	Stoichiometry and geometry of the CXC chemokine receptor 4 complex with CXC ligand 12: Molecular modeling and experimental validation. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5363-72.	3.3	70
104	Structural basis for activation of trimeric Gi proteins by multiple growth factor receptors via GIV/Girdin. Molecular Biology of the Cell, 2014, 25, 3654-3671.	0.9	54
105	PeptiSite: A structural database of peptide binding sites in 4D. Biochemical and Biophysical Research Communications, 2014, 445, 717-723.	1.0	13
106	Docking to multiple pockets or ligand fields for screening, activity prediction and scaffold hopping. Future Medicinal Chemistry, 2014, 6, 1741-1755.	1.1	15
107	Role of 3D Structures in Understanding, Predicting, and Designing Molecular Interactions in the Chemokine Receptor Family. Topics in Medicinal Chemistry, 2014, , 41-85.	0.4	1
108	Advances in GPCR Modeling Evaluated by the GPCR Dock 2013 Assessment: Meeting New Challenges. Structure, 2014, 22, 1120-1139.	1.6	149

#	Article	IF	CITATIONS
109	In Silico Identification and Pharmacological Evaluation of Novel Endocrine Disrupting Chemicals That Act via the Ligand-Binding Domain of theÂEstrogen Receptor α. Toxicological Sciences, 2014, 141, 188-197.	1.4	36
110	Rational Design of Berberine-Based FtsZ Inhibitors with Broad-Spectrum Antibacterial Activity. PLoS ONE, 2014, 9, e97514.	1.1	82
111	Identification of a New Class of FtsZ Inhibitors by Structure-Based Design and <i>in Vitro</i> Screening. Journal of Chemical Information and Modeling, 2013, 53, 2131-2140.	2.5	65
112	Molecular Basis for Benzodiazepine Agonist Action at the Type 1 Cholecystokinin Receptor. Journal of Biological Chemistry, 2013, 288, 21082-21095.	1.6	19
113	BioSuper: A web tool for the superimposition of biomolecules and assemblies with rotational symmetry. BMC Structural Biology, 2013, 13, 32.	2.3	8
114	Quantum mechanics approaches to drug research in the era of structural chemogenomics. International Journal of Quantum Chemistry, 2013, 113, 1669-1675.	1.0	14
115	Lapatinib-Binding Protein Kinases in the African Trypanosome: Identification of Cellular Targets for Kinase-Directed Chemical Scaffolds. PLoS ONE, 2013, 8, e56150.	1.1	36
116	Pocketome: an encyclopedia of small-molecule binding sites in 4D. Nucleic Acids Research, 2012, 40, D535-D540.	6.5	149
117	Compound Activity Prediction Using Models of Binding Pockets or Ligand Properties in 3D. Current Topics in Medicinal Chemistry, 2012, 12, 1869-1882.	1.0	42
118	ALiBERO: Evolving a Team of Complementary Pocket Conformations Rather than a Single Leader. Journal of Chemical Information and Modeling, 2012, 52, 2705-2714.	2.5	42
119	Docking and scoring with ICM: the benchmarking results and strategies for improvement. Journal of Computer-Aided Molecular Design, 2012, 26, 675-686.	1.3	290
120	Computational chemistry in 25Âyears. Journal of Computer-Aided Molecular Design, 2012, 26, 9-10.	1.3	6
121	GPCR agonist binding revealed by modeling and crystallography. Trends in Pharmacological Sciences, 2011, 32, 637-643.	4.0	56
122	Structure based prediction of subtype-selectivity for adenosine receptor antagonists. Neuropharmacology, 2011, 60, 108-115.	2.0	81
123	Systematic Exploitation of Multiple Receptor Conformations for Virtual Ligand Screening. PLoS ONE, 2011, 6, e18845.	1.1	82
124	Status of GPCR Modeling and Docking as Reflected by Community-wide GPCR Dock 2010 Assessment. Structure, 2011, 19, 1108-1126.	1.6	269
125	Methods of Protein Structure Comparison. Methods in Molecular Biology, 2011, 857, 231-257.	0.4	378
126	Interactive JIMD articles using the iSee concept: turning a new page on structural biology data. Journal of Inherited Metabolic Disease, 2011, 34, 565-567.	1.7	6

#	Article	IF	CITATIONS
127	Ligand-Guided Receptor Optimization. Methods in Molecular Biology, 2011, 857, 189-205.	0.4	41
128	Structure-Based Discovery of Novel Chemotypes for Adenosine A <sub>2A</sub> Receptor Antagonists. Journal of Medicinal Chemistry, 2010, 53, 1799-1809.	2.9	231
129	Improved docking, screening and selectivity prediction for small molecule nuclear receptor modulators using conformational ensembles. Journal of Computer-Aided Molecular Design, 2010, 24, 459-471.	1.3	59
130	Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule Inhibitor. Chemistry and Biology, 2010, 17, 471-482.	6.2	538
131	Secretin Occupies a Single Protomer of the Homodimeric Secretin Receptor Complex. Journal of Biological Chemistry, 2010, 285, 9919-9931.	1.6	21
132	SimiCon: a web tool for protein–ligand model comparison through calculation of equivalent atomic contacts. Bioinformatics, 2010, 26, 2784-2785.	1.8	12
133	The <i>Pthaladyns</i> : GTP Competitive Inhibitors of Dynamin I and II GTPase Derived from Virtual Screening. Journal of Medicinal Chemistry, 2010, 53, 5267-5280.	2.9	50
134	Analysis of full and partial agonists binding to <i>β</i> <sub>2</sub> â€adrenergic receptor suggests a role of transmembrane helix V in agonistâ€specific conformational changes. Journal of Molecular Recognition, 2009, 22, 307-318.	1.1	113
135	Four-Dimensional Docking: A Fast and Accurate Account of Discrete Receptor Flexibility in Ligand Docking. Journal of Medicinal Chemistry, 2009, 52, 397-406.	2.9	172
136	The Flexible Pocketome Engine for Structural Chemogenomics. Methods in Molecular Biology, 2009, 575, 249-279.	0.4	55
137	A New Method for Publishing Three-Dimensional Content. PLoS ONE, 2009, 4, e7394.	1.1	37
138	Flexible ligand docking to multiple receptor conformations: a practical alternative. Current Opinion in Structural Biology, 2008, 18, 178-184.	2.6	456
139	Type-II Kinase Inhibitor Docking, Screening, and Profiling Using Modified Structures of Active Kinase States. Journal of Medicinal Chemistry, 2008, 51, 7921-7932.	2.9	162
140	New Method for the Assessment of All Drug-Like Pockets Across a Structural Genome. Journal of Computational Biology, 2008, 15, 231-240.	0.8	21
141	Disseminating structural genomics data to the public: from a data dump to an animated story. Trends in Biochemical Sciences, 2006, 31, 76-78.	3.7	42
142	Pocketome via Comprehensive Identification and Classification of Ligand Binding Envelopes. Molecular and Cellular Proteomics, 2005, 4, 752-761.	2.5	350
143	Optimal docking area: A new method for predicting protein-protein interaction sites. Proteins: Structure, Function and Bioinformatics, 2004, 58, 134-143.	1.5	185
144	ICM-DISCO docking by global energy optimization with fully flexible side-chains. Proteins: Structure, Function and Bioinformatics, 2003, 52, 113-117.	1.5	183

#	Article	IF	CITATIONS
145	Nuclear Hormone Receptor Targeted Virtual Screening. Journal of Medicinal Chemistry, 2003, 46, 3045-3059.	2.9	170
146	Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 7354-7359.	3.3	170
147	Structural model of nicotinic acetylcholine receptor isotypes bound to acetylcholine and nicotine. BMC Structural Biology, 2002, 2, 1.	2.3	103
148	In silico discovery of novel retinoic acid receptor agonist structures. BMC Structural Biology, 2001, 1, 1.	2.3	47
149	Rapid boundary element solvation electrostatics calculations in folding simulations: Successful folding of a 23-residue peptide. Biopolymers, 2001, 60, 124-133.	1.2	115
150	SCREENED CHARGE ELECTROSTATIC MODEL IN PROTEIN-PROTEIN DOCKING SIMULATIONS. , 2001, , .		4
151	Prediction of the binding energy for small molecules, peptides and proteins. , 1999, 12, 177-190.		146
152	Prediction of the binding energy for small molecules, peptides and proteins. , 1999, 12, 177.		1
153	Flexible protein–ligand docking by global energy optimization in internal coordinates. Proteins: Structure, Function and Bioinformatics, 1997, 29, 215-220.	1.5	334
154	Homology modeling with internal coordinate mechanics: Deformation zone mapping and improvements of models via conformational search. Proteins: Structure, Function and Bioinformatics, 1997, 29, 29-37.	1.5	58
155	A new method for modeling large-scale rearrangements of protein domains. , 1997, 27, 410-424.		39
156	Flexible protein–ligand docking by global energy optimization in internal coordinates. Proteins: Structure, Function and Bioinformatics, 1997, 29, 215-220.	1.5	44
157	Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins: Structure, Function and Bioinformatics, 1997, Suppl 1, 215-20.	1.5	139
158	Homology modeling with internal coordinate mechanics: deformation zone mapping and improvements of models via conformational search. Proteins: Structure, Function and Bioinformatics, 1997, Suppl 1, 29-37.	1.5	40
159	Recognition of distantly related proteins through energy calculations. Proteins: Structure, Function and Bioinformatics, 1994, 19, 132-140.	1.5	58
160	ICM?A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation. Journal of Computational Chemistry, 1994, 15, 488-506.	1.5	1,502
161	Efficient parallelization of the energy, surface, and derivative calculations for internal coordinate mechanics. Journal of Computational Chemistry, 1994, 15, 1105-1112.	1.5	11
162	Detailed ab initio prediction of lysozyme–antibody complex with 1.6 à accuracy. Nature Structural and Molecular Biology, 1994, 1, 259-263.	3.6	123

#	Article	IF	CITATIONS
163	Biased Probability Monte Carlo Conformational Searches and Electrostatic Calculations for Peptides and Proteins. Journal of Molecular Biology, 1994, 235, 983-1002.	2.0	901